News

Scottie Pippen Reacts to Michael Saylor’s Bold Bitcoin Forecast

Scottie Pippen Reacts to Michael Saylor’s Bold Bitcoin Forecast

Scottie Pippen Steps Into the Bitcoin Price Debate

In a twist that blends the worlds of basketball and crypto, NBA legend Scottie Pippen has revived the conversation around a bold Bitcoin price forecast from Michael Saylor. The spark? A playful social post from Pippen, where he joked that the mysterious Satoshi Nakamoto visited him in a dream with bullish predictions. The timing landed just as Saylor, long one of Bitcoin’s loudest voices, doubled down on his views about where the price could go next.

Michael Saylor’s Latest Take on Bitcoin

Michael Saylor, co-founder of MicroStrategy and a prominent Bitcoin advocate, recently joined CNBC’s Squawk Box to unpack the current market. He talked through pressure points like substantial outflows from spot Bitcoin ETFs, and then contrasted that backdrop with how MicroStrategy has held its ground—and, in his view, pulled ahead—amid heavy competition.

Saylor highlighted a headline number: MicroStrategy’s stock has surged more than 800% since mid-2020. He tied that run-up to a deliberate strategy of acquiring Bitcoin using funds raised through convertible notes. In his telling, those moves have helped the company outpace a range of names on the S&P 500 and have reinforced his conviction that Bitcoin isn’t just a curious experiment—it’s an investment asset with staying power.

The Big Number Behind Saylor’s Valuation Call

Pressed on whether capital might rotate out of gold and into Bitcoin, Saylor framed the stakes in global terms. If Bitcoin today represents roughly 0.1% of the world’s capital, he argued, a meaningful shift could see it capture as much as 7% before long. From that premise, he offered a headline-grabbing forecast: over the next 21 years, Bitcoin could reach about $13 million per coin.

That’s when Scottie Pippen jumped back into the mix. Building on his earlier dream gag, he teased Saylor by asking whether that eye-popping number also came courtesy of Satoshi Nakamoto during a late-night visit. The exchange kept the tone light while keeping the focus squarely on Bitcoin’s long-term upside—and the assumptions behind it.

Pippen’s Dream, One Number, and a Lot of Buzz

Pippen, for his part, has floated a dream-born number of his own: that Satoshi once told him Bitcoin would hit $84,650 on a specific date. It’s tongue-in-cheek, sure, but it also nods to the possibility of a new all-time high. Whether Pippen personally holds Bitcoin remains unclear. The bigger, on-the-record number sits with MicroStrategy, which has amassed a sizable Bitcoin position valued at around $8.3 billion.

Together, the back-and-forth shows how sports culture and crypto now share the same stage. Big personalities draw in believers and skeptics alike, and the noise amplifies when prices move. At the moment, Bitcoin trades around $57,070, up roughly 4.5%—enough to keep the conversation lively, and the predictions flowing.

Frequently Asked Questions

What did Michael Saylor predict about Bitcoin’s future price?

Saylor said that, over the next 21 years, Bitcoin could reach about $13 million per coin. He framed this around the idea that Bitcoin could grow from roughly 0.1% of global capital to as much as 7%.

How did Scottie Pippen add to the conversation?

Pippen kept things light by joking that Satoshi Nakamoto visited him in a dream—then used that setup to poke at Saylor’s forecast, asking if the same dream delivered that $13 million figure.

How has MicroStrategy performed since adopting its Bitcoin strategy?

MicroStrategy’s stock price has risen more than 800% since mid-2020, a run Saylor links to buying Bitcoin using proceeds from convertible notes and to the company’s position relative to many S&P 500 peers.

What is the current price of Bitcoin?

Right now, Bitcoin is trading around $57,070, up about 4.5%.

Do we know whether Scottie Pippen holds any Bitcoin?

No. There’s no confirmed information about Pippen’s personal Bitcoin holdings. The spotlight, instead, is on MicroStrategy’s large Bitcoin stash, valued at roughly $8.3 billion.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

SVRN Taps Industry Vet Patrick O'Kain as COO

Updated Category News Views 54

SVRN Aims for New Heights with a Savvy Hire If there’s one thing veteran market-watchers like myself know, it’s that leadership shifts can tell you more about a company’s guts than any press release. SVRN (NASDAQ: SVRN), a name with one foot firmly in the world of digital assets, just snagged Patrick O’Kain for their COO spot. They're not playing around, folks,...

Continue Reading
Survey Reveals 'TDS' Impact on 2026 Midterm Elections

Updated Category News Views 70

Midterms and 'Trump Derangement Syndrome': What's the Deal? Every election season there's something new to raise eyebrows, and this time it's 'Trump Derangement Syndrome' (TDS) taking the spotlight. After the dust of the 2026 mid-terms started settling, it turns out there's more than just traditional candidate bickering shaping votes. Can you guess what's driving voters?...

Continue Reading
Sempra Shines with Robust Q3 2026 Financials

Updated Category News Views 0

Strong Q3 Numbers Set the Scene It’s not every day you see a company cough up numbers that speak volumes. Sempra’s third quarter for 2026 paints a picture of solid performance, boasting earnings of $877 million or $1.34 per diluted share per GAAP standards. That’s an eye-opener compared to the paltry $77 million or $0.12 per share they reported same time last year....

Continue Reading
Coastal Financial Faces Class Action Suit Over Securities

Updated Category News Views 78

Securities Law Tangles: Coastal Financial Hits a Snag There's no dodging it—Coastal Financial Corporation's dogged by a class action lawsuit, and investors need to sit up and take notice. This kind of legal fracas can hit the stock price like a brick through a window, especially when alleged securities law violations crop up. DJS Law Group's got the reins on this one,...

Continue Reading
Grant Davis Joins Assembly Health as CXO

Updated Category News Views 101

Shuffling Pieces in Healthcare Management Change is constant in healthcare management, folks, and it's all about finding the right puzzle pieces. That's what Assembly Health has done by welcoming Grant Davis as their new Chief Experience Officer (CXO). Yeah, you heard me right. It's not a CEO or a CFO, but the CXO role that's under the spotlight this time around, aiming...

Continue Reading
MAURE's Three-Year Mark: Crafting Home Elegance

Updated Category News Views 53

Brooklyn's Gem: MAURE Turns Three Over in Brooklyn, there's a brand bubbling with style called MAURE. Now, we're talking three years strong, surviving the wild bout of the retail scene with a firm two feet planted in home and gifting. The Vision Turned Reality When Maureen Cavalieri, a hospitality veteran since 2009, first tossed this spark into the wind in 2023, it...

Continue Reading
Dizal Unveils Promising Data at ASH 2026

Updated Category News Views 72

Pushing the Horizons in Hematological Research From the bustling streets of Shanghai to the global stage of the ASH 2026, Dizal has made its mark again. This year's presentations could very well shake up the hematological landscape, showcasing new possibilities for treatment strategies. Golidocitinib: A Game-Changer? Now here's a ticket we've been watching with some high...

Continue Reading
LOA Roofing's Growth Recap Taps Southstone's Backing

Updated Category News Views 107

Pardon my skepticism, but when a roofing company names itself Life of Abundance, you know they're aiming to hit it big or at least make you think they're onto something special. LOA Roofing and Construction, holding its ground as a major player in the Central Texas market, set the stage for more ambitious growth. And they found themselves a dance partner in Southstone...

Continue Reading
SKF's Industrial Push: Energy Efficiency at COP31

Updated Category News Views 17

SKF's Green Initiative: A Major Step Forward You ever find yourself in a room full of big players, each trying to outdo the other? That's the stage set for SKF at COP31, where they're not just strutting around showing off but actually offering some substance—a rarity in these highbrow gatherings. They're juicing up the talk around energy efficiency and circularity...

Continue Reading
Eli Lilly's Retatrutide Trials Signal Innovation

Updated Category News Views 48

Unpacking Lilly's Latest Rheumatology Innovations Lilly's taking the stage at ACR Convergence 2026 with a potent arsenal of data that’s got folks buzzing. The company’s put the pedal to the metal on understanding the intertwining chords of obesity and rheumatologic conditions, and boy, are they not messing around. Retatrutide: A Triple Threat in the Making Headlining...

Continue Reading

Top 5 Most Recently Viewed Articles

SKYX Technologies Expands Market Presence with Insider Investments

Updated Category News Views 166

SKYX Technologies' Corporate Developments SKYX Technologies, also known as SKYX (NASDAQ: SKYX), is taking significant strides in the smart technology sector. This dynamic company focuses on transforming homes and buildings into smarter, safer, and more advanced spaces. With a remarkable portfolio of over 97 issued and pending patents, SKYX aims to set a new standard in...

Continue Reading
Crinetics Pharmaceuticals Expands Workforce With Stock Options

Updated Category News Views 195

Crinetics Pharmaceuticals Enhances Employee Incentives In a recent announcement, Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), based in San Diego, revealed a significant step in enhancing employee incentives and strengthening its workforce. On October 10, 2025, the company’s Compensation Committee authorized the granting of stock options and restricted stock units...

Continue Reading
Manulife Investment Management Earns Top Recognition in Sustainable Finance

Updated Category News Views 199

Manulife Investment Management Recognized for Excellence In a significant acknowledgment of its leadership in sustainable finance, Manulife Investment Management (Manulife IM) has made it to the prestigious list of IPE Real Assets' Top 50 Natural Capital Managers. This recognition comes as the firm is gearing up for robust fundraising activities, with an exciting fund...

Continue Reading
Vaxart Reports Progress and Financial Performance for Q3 2025

Updated Category News Views 213

Vaxart’s Business Progress and Financial Results Overview Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company, recently provided a significant update on its business and reported its financial outcomes for the third quarter of 2025. This latest communication showcases exciting developments in their oral recombinant vaccine platform, which is designed to...

Continue Reading
Madrigal Pharmaceuticals Marks Enrollment Milestone in NASH Study

Updated Category News Views 47

Madrigal Pharmaceuticals Achieves Enrollment Milestone in NASH Study Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company dedicated to developing innovative therapies for liver diseases, has announced a significant milestone in their MAESTRO-NASH OUTCOMES clinical trial. This study evaluates the efficacy of resmetirom in patients diagnosed with...

Continue Reading